Loading clinical trials...
Loading clinical trials...
An Open Label, Randomized, Single Dose, Two-way Crossover , Two-Period, Two-Treatment, Two-Sequence Bioequivalence Study of Klaribact Tablet (Clarithromycin 500 mg), Compared With Reference Product, Klaricid Tablet (Clarithromycin 500 mg) in Healthy Adult Male Subjects
Conditions
Interventions
Klaribact 500 mg Clarithromycin Tablet
Klaricid 500 mg Clarithromycin Tablet
Locations
1
Pakistan
Center for Bioequivalence Studies and clinical research (CBSCR), ICCBS
Karachi, Sindh, Pakistan
Start Date
October 23, 2012
Primary Completion Date
November 2, 2012
Completion Date
December 25, 2012
Last Updated
September 7, 2022
NCT07310264
NCT06342713
NCT07472361
NCT06649110
NCT06823947
NCT07240675
Lead Sponsor
University of Karachi
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions